A second fly species just earned FDA clearance to eat dead human tissue for a living. On June 15, 2026, Cuprina Holdings announced that MEDIFLY Maggots — sterile larvae of the Australian sheep blowfly, Lucilia cuprina — received 510(k) clearance for debriding chronic, non-healing wounds. That includes diabetic foot ulcers, pressure ulcers, and post-surgical wounds that refuse to cooperate.

The mechanism sounds like a horror movie pitch that accidentally works. Larvae secrete enzymes that liquefy necrotic tissue, ingest the slurry, and potentially disrupt bacterial biofilms — all while sparing living flesh. Think of it as nose-to-tail dining at a Michelin-starred table: the concept repulses you, but the results are harder to argue with.

One critical distinction worth making: these are carrion feeders, not flesh eaters. That matters right now, as the U.S. contends with New World screwworm concerns — a genuinely dangerous parasitic fly that attacks living tissue. Medical maggots are a different category entirely.

Here’s what you need to know:

• Lucilia cuprina is the newly cleared species; Lucilia sericata (green bottle fly) has been cleared since 2004
• Both cover necrotic pressure ulcers, diabetic foot ulcers, and non-healing traumatic wounds
• Cuprina now holds commercial FDA rights to both species — no other company does
• A prospective case-control study found a 20% amputation rate with maggot therapy versus 38% with conventional care, though the sample was too small for statistical significance
• Large randomized trials remain lacking; maggot debridement therapy remains a last-resort option in most wound-care protocols

Ronald Sherman, Cuprina’s Medical and Scientific Director, stated that MDT “has earned its place in modern wound care, and adding a second FDA-cleared species strengthens the entire field,” according to reporting by Ars Technica.

One Company, Two Species, Zero Competition

Cuprina’s stock doubled overnight, but the real question is whether clinicians will prescribe what patients instinctively recoil from.

The business angle is direct. Cuprina now operates what amounts to a regulatory monopoly in medical maggots. CEO David Quek called it “a unique position that no other company has,” citing a competitive advantage in a demanding market, according to a company filing. The stock surged more than 100% on the news.

The two species aren’t therapeutically different — Cuprina doesn’t claim otherwise. L. cuprina serves markets in Australia, Asia, and Africa, where it’s already recognized, while L. Serica dominates Western wound care. It’s geographic positioning, not clinical superiority. Notably, the FDA’s Center for Biologics Evaluation and Research assumed oversight of medical maggots in December 2024, aligning them more closely with biologic-type products.

FDA clearance is the easy part. The harder sell is overcoming decades of the “ick factor” that has kept a centuries-old therapy sidelined. Your clinician might know maggot therapy works. Recommending it to you is an entirely different conversation. Until robust trial data arrive, medical maggots will remain exactly what they’ve always been: effective, underused, and deeply unsettling.